Dynavax Technologies Announces Pricing of $70.0 Million Public Offering of Common StockGlobeNewsWire • 05/22/20
Dynavax Technologies Corporation (DVAX) CEO Ryan Spencer on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/08/20
Dynavax Technologies (DVAX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 ReleaseZacks Investment Research • 04/30/20
Dynavax and Sinovac Announce Collaboration to Develop a Coronavirus (COVID-19) VaccineGlobeNewsWire • 04/16/20
Dynavax Donates 10,000 Doses of HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted] Vaccine to Emergency Healthcare Providers and Hospital Staff to Protect Against Hepatitis B Infections Amidst COVID-19 PandemicGlobeNewsWire • 04/08/20
Dynavax New Vaccine: Are Investors Sick of Coronavirus Vaccine Stocks Yet?24/7 Wall Street • 03/26/20
Dynavax and CEPI Announce Collaboration to Support Global Effort to Develop a Vaccine for Coronavirus (COVID-19)GlobeNewsWire • 03/26/20
Dynavax and Clover Biopharmaceuticals Announce Research Collaboration to Evaluate Coronavirus (COVID-19) Vaccine Candidate with CpG 1018 AdjuvantGlobeNewsWire • 03/24/20
Dynavax Technologies (DVAX) Reports Q4 Loss, Misses Revenue EstimatesZacks Investment Research • 03/11/20
Dynavax Announces Collaboration with the University of Queensland and the Coalition for Epidemic Preparedness (CEPI) Focused on the Development of a Coronavirus (COVID-19) VaccineGlobeNewsWire • 03/02/20
Dynavax Appoints Ryan Spencer as Chief Executive Officer and to Board of DirectorsGlobeNewsWire • 12/16/19
Dynavax Announces Partnership with Albertsons Companies’ Pharmacies to Offer HEPLISAV-B® Hepatitis B Vaccine to Patients NationwideGlobeNewsWire • 12/05/19